NASDAQ:KALV

KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis

$11.21
-0.23 (-2.01%)
(As of 04/23/2024 ET)
Today's Range
$11.19
$11.71
50-Day Range
$11.04
$14.86
52-Week Range
$7.21
$16.88
Volume
192,444 shs
Average Volume
732,852 shs
Market Capitalization
$472.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.33

KalVista Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
134.9% Upside
$26.33 Price Target
Short Interest
Bearish
13.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.94mentions of KalVista Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$1.96 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.05) to ($2.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

176th out of 909 stocks

Pharmaceutical Preparations Industry

65th out of 425 stocks

KALV stock logo

About KalVista Pharmaceuticals Stock (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

KALV Stock Price History

KALV Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
KalVista Pharmaceuticals (NASDAQ: KALV)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
See More Headlines
Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/23/2024
Fiscal Year End
4/30/2024
Next Earnings (Estimated)
7/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KALV
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.33
High Stock Price Target
$35.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+134.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-92,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.71 per share

Miscellaneous

Free Float
36,999,000
Market Cap
$472.95 million
Optionable
Optionable
Beta
0.88
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Benjamin L. Palleiko (Age 58)
    CEO & Director
    Comp: $707.1k
  • Dr. Christopher M. Yea Ph.D. (Age 60)
    Chief Development Officer
    Comp: $640.23k
  • Dr. Edward P. Feener Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $506k
  • Mr. Ryan Baker
    Head of Investor Relations
  • Mr. Brian Krex J.D. (Age 56)
    General Counsel
  • Jarrod Aldom
    Vice President of Corporate Communications
  • Ms. Rachel M. Morten
    Senior Vice President of Regulatory Affairs & QA
  • Dr. Michael D. Smith Pharm.D. (Age 44)
    Senior Vice President of Development
  • Dr. Paul K. Audhya M.B.A. (Age 51)
    M.D., Chief Medical Officer
  • Ms. Nicole Sweeny (Age 48)
    Chief Commercial Officer

KALV Stock Analysis - Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KALV shares.
View KALV analyst ratings
or view top-rated stocks.

What is KalVista Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 1-year price objectives for KalVista Pharmaceuticals' stock. Their KALV share price targets range from $20.00 to $35.00. On average, they predict the company's share price to reach $26.33 in the next twelve months. This suggests a possible upside of 134.9% from the stock's current price.
View analysts price targets for KALV
or view top-rated stocks among Wall Street analysts.

How have KALV shares performed in 2024?

KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of the year. Since then, KALV shares have decreased by 8.5% and is now trading at $11.21.
View the best growth stocks for 2024 here
.

Are investors shorting KalVista Pharmaceuticals?

KalVista Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the March 15th total of 4,920,000 shares. Based on an average daily volume of 809,700 shares, the short-interest ratio is currently 6.8 days.
View KalVista Pharmaceuticals' Short Interest
.

When is KalVista Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, July 5th 2024.
View our KALV earnings forecast
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings results on Monday, March, 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.09.

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KALV) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners